Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 08379067 approvals12 trials

CG Invites Co., Ltd.

Official website

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

As of 2026-10-10, CG Invites Co., Ltd. has 65 Korean MFDS device approvals, 2 Korean MFDS drug approvals, 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Established in 2000 and listed on KOSDAQ in 2006, the company is a genomics, drug development, and AI healthcare solutions firm. Its pipeline includes the NSAID Acelex for osteoarthritis, the HDAC-targeting anticancer agent ivaltinostat (CG-745), and the PD-1 immune checkpoint inhibitor camrelizumab (SHR-1210), alongside its AI-driven digital healthcare operating system 'Invites Loop.' In December 2024 it won a KRW 6.16 billion project from the Korea Research Institute of Bioscience and Biotechnology for genome and transcriptome data production and analysis (Dec 3, 2024 - Dec 15, 2026).

Products & technology

  • AcelexNSAID for osteoarthritis

Regulatory approvals

data.go.kr

2 Korean MFDS drug approvals · 2015–2019 / 65 Korean MFDS device approvals · 2013–2023

  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-444 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-443 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-442 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-441 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-440 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-27
    Product approval · Class 3체외 제허 23-439 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-03-09
    Product approval · Class 3체외 제허 23-279 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2021-03-12
    Product approval · Class 3체외 제허 21-187 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-11-23
    Product approval · Class 3체외 제허 20-988 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-04-09
    Product approval · Class 3체외 제허 20-270 호
  • MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnostics2019-12-26
    Product approval · Class 2체외 제인 19-5049 호
  • MFDS drugAcelex Tab. 2mg2019-10-30
    Drug · Prescription · Approval201907587
Show 55 more
  • MFDSOther reagents, classⅡ, for molecular diagnostics2019-01-03
    Product approval · Class 2체외 제인 19-4 호
  • MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnostics2018-07-30
    Product approval · Class 2체외 제인 18-4605 호
  • MFDSIVD reagents for genotyping or patient monitoring of HIV, HBV, HCV, HTLV, molecular diagnosticsRevoked2018-07-26
    Product approval · Class 3체외 제허 18-535 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2018-07-26
    Product approval · Class 3체외 제허 18-534 호
  • MFDS drugAcelex Cap. 2mg2015-02-05
    Drug · Prescription · Approval201500622
  • MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnostics2013-08-12
    Product approval · Class 2체외 제인 13-1422 호
  • MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnostics2013-08-08
    Product approval · Class 2체외 제인 13-1412 호
  • MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnostics2013-08-08
    Product approval · Class 2체외 제인 13-1413 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-06-03
    Product approval · Class 3체외 제허 13-965 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-05-14
    Product approval · Class 3체외 제허 13-851 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-05-13
    Product approval · Class 3체외 제허 13-839 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-02-28
    Product approval · Class 3체외 제허 13-476 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-02-28
    Product approval · Class 3체외 제허 13-473 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-02-28
    Product approval · Class 3체외 제허 13-474 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-02-28
    Product approval · Class 3체외 제허 13-475 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-02-28
    Product approval · Class 3체외 제허 13-472 호
  • MFDSOther reagents, classⅡ, for molecular diagnostics2013-02-12
    Product approval · Class 2체외 제인 13-360 호
  • MFDSIVD reagents for genotyping or patient monitoring of HIV, HBV, HCV, HTLV, molecular diagnosticsRevoked2013-01-08
    Product approval · Class 3체외 제허 13-164 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-08
    Product approval · Class 3체외 제허 13-165 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-141 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-07
    Product approval · Class 3체외 제허 13-142 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-143 호
  • MFDSIVD reagents for genotyping or patient monitoring of HIV, HBV, HCV, HTLV, molecular diagnosticsRevoked2013-01-07
    Product approval · Class 3체외 제허 13-144 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-145 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-146 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-147 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-07
    Product approval · Class 3체외 제허 13-148 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-45 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-02
    Product approval · Class 3체외 제허 13-46 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-02
    Product approval · Class 3체외 제허 13-84 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-85 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-86 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-02
    Product approval · Class 3체외 제허 13-87 호
  • MFDSIVD reagents for Infectious disease marker(Drug resistant microorganism)2013-01-02
    Product approval · Class 3체외 제허 13-88 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-89 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-90 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-91 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-92 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-93 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-94 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-95 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-96 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-97 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-98 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-99 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-100 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-02
    Product approval · Class 3체외 제허 13-101 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-102 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-103 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-104 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-105 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-106 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2013-01-02
    Product approval · Class 3체외 제허 13-107 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-108 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2013-01-02
    Product approval · Class 3체외 제허 13-109 호

Clinical trials

data.go.kr

12 MFDS clinical trial authorisations · 2012–2023 (Phase 1 6 · Phase 1/2 3 · Phase 2 2 · Phase 3 1)

  • Phase 2캄렐리주맙(SHR-1210)2023-02-20

    9 trial sites

  • Phase 2CG-CAM202020-07-01

    1 trial site

  • Phase 1아이발티노스타트(Ivaltinostat) 캡슐2019-08-08

    1 trial site

  • Phase 1CG-6512019-06-21

    1 trial site

  • Phase 1아셀렉스정2밀리그램 (CGL1802)2018-11-29

    1 trial site

  • Phase 1CG1006502018-03-23

    1 trial site

  • Phase 1/2아이발티노스타트(Ivaltinostat) 캡슐2017-01-10

    1 trial site

  • Phase 1아셀렉스정2밀리그램 (CGL1802)2017-01-03

    1 trial site

  • Phase 1/2아이발티노스타트(Ivaltinostat) 캡슐2015-11-12

    1 trial site

  • Phase 1/2아이발티노스타트(Ivaltinostat) 캡슐2015-03-19

    3 trial sites

  • Phase 1아이발티노스타트(Ivaltinostat) 캡슐2013-10-30

    1 trial site

  • Phase 3CG1006492012-10-25

    14 trial sites

R&D and key agreements

Source: DART corporate disclosure

아이발티노스타트(CG-745) · 골수형성이상증후군(MDS), 췌장암 · 임상2상 · HDAC-targeting anticancer agent; pancreatic cancer Phase 2 completed Mar 2020; FDA IND approval for Phase 1b/2 Jan 2022; licensed to CG Pharmaceuticals, Inc. in 2024

캄렐리주맙(Camrelizumab, SHR-1210) · 비소세포폐암(non-squamous NSCLC) · 가교임상 · PD-1 immune checkpoint inhibitor; Phase 3 completed in China/globally for esophageal and liver cancer; bridging trial ongoing in Korea for non-squamous NSCLC

Key disclosures

KRX KIND via OpenDART
Show 6 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 83 more patents

AI reads

MAA server logs · IP-verified
253
Times AI engines pulled CG Invites Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

252
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

26
live 0
Last 7 days
204
live 1
Last 30 days
253
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot201
  • GoogleGoogleOther37
  • PerplexityPerplexityBot12
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for CG Invites Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BIONEERCORPORATION4 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

LabGenomics. Co., Ltd.3 shared

KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.

Boditech Med Inc.2 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

OSANG HEALTHCARE CO.,LTD.2 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

iNtRON Biotechnology, Inc.2 shared

Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.

HLB PANAGENE Co., LTD.2 shared

Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.

GENEMATRIX INC.2 shared

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SEEGENE, INC.2 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

GENOTECH CORP.2 shared

Supplies synthetic genes (GenOligo) and DNA sequencing analysis services for biotech research.

Genomictree Inc.2 shared

Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.

SD BIOSENSOR INC.2 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

NanoenTek,Inc.1 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition